Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534122 | 1.00 | GSTO1 (0.34) | GSTO1HDAC1HDAC8HDAC6MCL1 | |
| SCHEMBL533883 | 0.87 | GSTO1 (0.38) | GSTO1HDAC1HDAC8HDAC6MCL1 | |
| SCHEMBL533622 | 0.80 | GRM5 (0.36) | GSTO1MCL1F2 | |
| SCHEMBL534621 | 0.78 | GSTO1 (0.34) | GSTO1HDAC1HDAC8HDAC6MCL1 | |
| SCHEMBL10316776 | 0.78 | KDM4E (0.32) | KDM4ENPC1RAB9A | |
| SCHEMBL10316777 | 0.78 | KDM4E (0.32) | KDM4ENPC1RAB9A | |
| SCHEMBL534180 | 0.77 | KDM4E (0.30) | KDM4E | |
| SCHEMBL534179 | 0.77 | KDM4E (0.30) | KDM4E | |
| SCHEMBL534536 | 0.77 | NR1H2 (0.34) | GSTO1HDAC1HDAC8HDAC6MCL1 | |
| SCHEMBL534154 | 0.74 | CYP1A2 (0.52) | KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676720-B2 | Substituted biaryl compound | UBE INDUSTRIES, LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE INDUSTRIES, LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| EP-3042656-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | UBE Industries, Ltd. (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2980075-A1 | SUBSTITUTED BIARYL COMPOUND | UBE Industries, Ltd. (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2476668-B1 | ANILINE COMPOUNDS | UBE INDUSTRIES (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120184747-A1 | ANILINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2476678-A1 | SUBSTITUTED CARBONYL COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2476668-A1 | ANILINE COMPOUNDS | Ube Industries, Ltd. (JP) | 2012-07-18 | — | — | EP | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184747-A1 | ANILINE COMPOUND | PTGER2, ADRB2, PTGER1 | GSTO1 2310/4885HDAC1 785/4885HDAC8 1243/4885 |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | GSTO1 1723/4885HDAC1 994/4885HDAC8 1664/4885 |
| US-20160060221-A1 | SUBSTITUTED BIARYL COMPOUND | FIBP, FGF2, FGFR2 | GSTO1 1279/4885HDAC1 74/4885HDAC8 652/4885 |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | GSTO1 2621/4885HDAC1 1052/4885HDAC8 2222/4885 |
| US-20160213657-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PULMONARY DISEASE | CFTR, ADRB3, ADRB2 | GSTO1 517/4885HDAC1 252/4885HDAC8 791/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | GSTO1 2686/4885HDAC1 1320/4885HDAC8 2197/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | GSTO1 3640/4885HDAC1 2557/4885HDAC8 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.